TAB Pharmaceuticals Consumer Health B.V. – Trademark Portfolio
Entity Type: 99
TAB Pharmaceuticals Consumer Health B.V. holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 4 Nice Classification classes. Currently, 0 trademarks are registered and 4 are pending. The owner is based in Amsterdam.
Eerste Weteringplantsoen 8
Amsterdam 1017SK , NL
Showing of trademarks Trademarks
Trademark Classifications
TAB Pharmaceuticals Consumer Health B.V.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does TAB Pharmaceuticals Consumer Health B.V. have?
TAB Pharmaceuticals Consumer Health B.V. has 8 U.S. trademarks filed with the USPTO. Of these, 4 pending, 4 abandoned.
What trademark classes does TAB Pharmaceuticals Consumer Health B.V. file in?
TAB Pharmaceuticals Consumer Health B.V. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What is TAB Pharmaceuticals Consumer Health B.V.'s trademark registration success rate?
TAB Pharmaceuticals Consumer Health B.V. has a 0% trademark registration rate, with 0 out of 4 resolved applications resulting in successful registration. Currently, 4 applications are pending review.